Arena Pharmaceuticals (ARNA) and United Therapeutics (UTHR) announced on Nov. 15 that the two companies have reached a deal on the pulmonary arterial hypertension (PAH) drug Ralinepag. The $1.2 billion deal is the type of deal that many Arena investors have anticipated.
Johns Hopkins spinout AsclepiX Therapeutics raised $5 million in new funding that will assist in development of new treatment for eye diseases that are leading causes of blindness in adults.
California Life Sciences Association (CLSA), the trade association representing California’s life sciences industry, and PwC US, are proud to release the 2019 California Life Sciences Industry Report. With over 350 data points, this 2019 Report provides a snapshot of California’s life sciences community, and how the world’s largest life sciences cluster remains a global hub for innovation, creating high-wage jobs, bringing new therapies and technologies to patients, and attracting significant investment from venture capitalists, the NIH and more.
Telehealth is changing the face of healthcare, and Medicare must adapt, said the CMS administrator.
Innovation is vital to the evolution and sustainability of the American healthcare system, and the Centers for Medicare & Medicaid Services (CMS) is working to be part of the transformation, according to its administrator.
The audience seated in an intimate ballroom at the University of Maryland, Baltimore (UMB) on Nov. 9 turned its attention to a small stage at the front of the room. The stage filled with red light as Nadine M. Finigan-Carr, PhD, MS, a research associate professor at the University of Maryland School of Social Work (UMSSW), entered from behind a black curtain off to the right.
Advanced analysis of genomic data integrated with electronic medical records and other data sets, combined with effective reimbursement strategies and full data-regulatory compliance, will distinguish winning diagnostics companies.
Virginia emerged as a winner in the fierce, nationwide competition to house a headquarters for Amazon. The commonwealth stepped up with a standout higher education package, including a new Virginia Tech Innovation Campus in Alexandria, which will be located less than two miles from Amazon’s new location in Arlington.
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve outcomes in cancers that are difficult to treat, today announced that Douglas J. Swirsky, who has served as Rexahn’s president and chief financial officer since January 2018, has been named the company’s president and chief executive officer and appointed to the company’s board of directors effective immediately. Peter D. Suzdak, Ph.D., chief executive officer, has departed the company and resigned as a member of its board of directors.
SERAXIS Inc., a rapidly growing regenerative medicine company today announced the publication of important trial considerations for SR-01, its pluripotent stem cell-derived islet therapy for insulin-dependent diabetes.
Gene editing company CRISPR Therapeutics and cell-based medicines and life sciences firm MaxCyte have expanded clinical and commercial license agreement into oncology.
